| Literature DB >> 24314052 |
Pouya Khankhanian1, Sergio E Baranzini, Britt A Johnson, Lohith Madireddy, Dorothee Nickles, Lisa A Croen, Yvonne W Wu.
Abstract
BACKGROUND: Cerebral palsy (CP) is a group of nonprogressive disorders of movement and posture caused by abnormal development of, or damage to, motor control centers of the brain. A single nucleotide polymorphism (SNP), rs1800795, in the promoter region of the interleukin-6 (IL6) gene has been implicated in the pathogenesis of CP by mediating IL-6 protein levels in amniotic fluid and cord plasma and within brain lesions. This SNP has been associated with other neurological, vascular, and malignant processes as well, often as part of a haplotype block.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24314052 PMCID: PMC3881497 DOI: 10.1186/1471-2350-14-126
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Figure 1Experimental design. Experimental workflow: sample sizes, number and type of variants identified, and analyses performed.
Genetic association with CP
| −174 | C/C versus G/G | 2.5 | 1.4-4.6 | 0.002 | 0.03 | Promoter | |
| 615 | A/A versus G/G | 2.7 | 1.4-5.5 | 0.001 | 0.02 | Intron | |
| 846 | C/C versus T/T | 2.4 | 1.3-4.6 | 0.004 | 0.05 | Intron | |
| 1090 | C/C versus G/G | 1.5 | 0.6-3.6 | 0.33 | 1 | Intron | |
| 1306 | C/C versus A/A | 1.8 | 0.8-3.6 | 0.1 | 0.9 | Intron | |
| 1889 | T/T versus G/G | 2.5 | 1.5-4.5 | 0.0005 | 0.007 | Intron | |
| 3331 | G/G versus A/A | 2.3 | 1.2-4.3 | 0.009 | 0.09 | CpG site* | |
| | 3.0 | 1.5-6.0 | 0.0007 | 0.004 | | ||
| | 4.3 | 2.0-10.1 | 0.00007 | 0.0004 | | ||
| | |||||||
| −174 | C/G versus G/G | 1.3 | 0.8-2.0 | 0.33 | 1 | Promoter | |
| 615 | A/G versus G/G | 1.3 | 0.8-2.0 | 0.28 | 1 | Intron | |
| 846 | C/T versus T/T | 1.4 | 0.9-2.1 | 0.19 | 1 | Intron | |
| 1090 | C/G versus G/G | 1 | 0.6-1.7 | 1 | 1 | Intron | |
| 1306 | C/A versus A/A | 0.7 | 0.3-1.8 | 0.5 | 1 | Intron | |
| 1889 | T/G versus G/G | 1.1 | 0.8-1.7 | 0.5 | 1 | Intron | |
| 3331 | G/A versus A/A | 1 | 0.5-2.3 | 1 | 1 | CpG site* | |
| | 1 | 0.6-1.6 | 1 | 1 | | ||
| 1 | 0.5-1.7 | 0.9 | 1 | ||||
*[27]; wt = wildtype; OR = odds ratio; CI = confidence interval; Bonf = Bonferroni correction for multiple hypothesis testing. For SNPs, correction was done for 14 total common SNPs tested.
aThe 4-SNP block includes rs1800795, rs2069832, rs2069833, rs1474348. It was one of five haplotypes identified in African American controls. Bonferroni correction for five hypotheses tested.
bThe 7-SNP block includes all SNPs listed in table. It was one of five haplotypes identified in white controls, one of three in Hispanic controls, and one of three in Asian controls. Bonferroni correction for 5 hypotheses tested.
Figure 2Subgroup analysis. Mean (boxes) and 95% confidence intervals (lines) for carriers of the variant haplotype by ethnicity, birth weight, and sex. Increased risk for homozygote carriers reached statistical significance in whites, Hispanics (one-sided only), males, and females (one-sided only). There was no risk associated with heterozygote carriers in any subgroup.
Clinical characteristics of frameshift carriers
| Moderate | 2 | |
| | Severe | 6 |
| Hemiparesis | 4 | |
| | Quadriparesis | 2 |
| | Paraparesis | 1 |
| | Monoparesis | 1 |
| Perinatal Stroke | 3 | |
| Global injury / volume loss | 2 | |
| | No abnormalities | 2 |
| | No imaging | 1 |
| Emergent Caesarian | 4 | |
| Preeclampsia | 1 | |
| | Maternal temp < 100.5 | 1 |
| | Meconium | 1 |
| Neonatal seizures | 2 |
*Moderate/severe = impaired function of most affected limb; mild = unimpaired function.
^All patients were diagnosed by a pediatric neurologist. Spasticity was present in all 8 patients; none had extra-pyramidal signs.